

BIOCON GROUP

FACT SHEET

June - 2020

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	June 30, 2020	March 31, 2020
ASSETS		
Non-current assets		
(a) Property, plant and equipment	5,404	5,393
(b) Capital work-in-progress	1,677	1,577
(c) Goodwill	26	26
(d) Other intangible assets	405	423
(e) Intangible assets under development	663	620
(f) Right-of-use assets	125	128
(g) Financial assets		
Investments	70	94
Derivative assets	26	26
Other financial assets	58	56
(h) Income tax asset, net	267	242
(i) Deferred tax asset, net	393	368
(j) Other non-current assets	138	151
Non-current assets	9,252	9,104
Current assets		
(a) Inventories	1,446	1,436
(b) Financial assets		
Investments	936	858
Trade receivables	1,309	1,173
Cash and cash equivalents	978	910
Other bank balances	193	89
Derivative assets	16	19
Other financial assets	543	450
(c) Other current assets	352	340
(c) Assets held for sale	76	65
Current assets	5,849	5,340
TOTAL - ASSETS	15,101	14,444
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	600
(b) Other equity	6,261	6,106
Equity attributable to owners of the Company	6,861	6,706
Non-controlling interests	706	677
Total Equity	7,567	7,383
Non-current liabilities		
(a) Financial liabilities		
Borrowings	1,491	1,222
Lease liabilities	81	83
Derivative liabilities	131	146
Other financial liabilities	537	536
(b) Provisions	89	86
(c) Deferred tax liability, net	30	30
(d) Other non-current liabilities	976	949
Non-current liabilities	3,335	3,053
Current liabilities		
(a) Financial liabilities		
Borrowings	764	668
Lease liabilities	8	7
Trade payables	1,405	1,277
Derivative liabilities	118	72
Other financial liabilities	1,109	1,208
(b) Provisions	111	103
(c) Income tax liability, net	201	128
(d) Other current liabilities	418	498
(e) Liabilities classified as held for sale	67	48
Current liabilities	4,199	4,008
TOTAL - EQUITY AND LIABILITIES	15,101	14,444

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	Q1'FY 21	Q1'FY 20	Variance %
INCOME			
Generics	599	516	16%
Biosimilars	692	582	19%
Novel Biologics	-	-	-
Research services	422	421	0%
Inter-segment	(41)	(60)	-32%
Revenue from operations #	1,671	1,459	15%
Other income	18	24	-24%
TOTAL REVENUE	1,690	1,483	14%
EXPENDITURE			
Material & Power costs	603	485	24%
Staff costs	359	309	16%
Research & Development expenses*	107	79	35%
Other expenses	190	149	28%
Manufacturing, staff & other expenses	1,258	1,021	23%
EBITDA	432	462	-6%
Interest & Finance charges	13	17	-25%
Depreciation & Amortisation	167	124	34%
PBT BEFORE EXCEPTIONAL ITEM	252	321	-21%
Exceptional item, Net	-	-	-
PBT FROM CONTINUING OPERATIONS	252	321	-21%
Taxes	81	69	18%
Taxes on exceptional item	-	17	-100%
NET PROFIT BEFORE MINORITY INTEREST	171	236	-27%
Minority interest	18	21	-14%
NET PROFIT FOR THE PERIOD FROM CONTINUING OPERATIONS	153	214	-29%
LOSS FROM DISCONTINUING OPERATION	4	8	-54%
NET PROFIT FOR THE PERIOD	149	206	-28%
EPS Rs.	1.2	1.7	
NET PROFIT BEFORE EXCEPTIONAL ITEM AND DISCONTINUING OPERATION	153	231	-34%
Loss from discontinuing operation	4	8	-54%
Exceptional item, net of taxes	-	(17)	-100%
NET PROFIT FOR THE PERIOD	149	206	-28%
<i># Licensing Income</i>	<i>10</i>	<i>7</i>	
<i>* Gross Research & Development expenses</i>	<i>142</i>	<i>110</i>	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			
(Rs. Crores)			
Particulars	Q1' FY 21	Q4' FY 20	Variance %
INCOME			
Generics	599	562	7%
Biosimilars	692	433	60%
Novel Biologics	-	-	-
Research services	422	607	-31%
Inter-segment	(41)	(45)	-10%
Revenue from operations #	1,671	1,558	7%
Other income	18	63	-71%
TOTAL REVENUE	1,690	1,621	4%
EXPENDITURE			
Material & Power costs	603	601	0%
Staff costs	359	354	1%
Research & Development expenses*	107	125	-15%
Other expenses	190	159	19%
Manufacturing, staff & other expenses	1,258	1,239	2%
EBITDA	432	382	13%
Interest & Finance charges	13	17	-26%
Depreciation & Amortisation	167	152	9%
PBT FROM CONTINUING OPERATIONS	252	213	19%
Taxes	81	45	80%
NET PROFIT FROM CONTINUING OPERATIONS	171	168	2%
Minority interest	18	36	-48%
NET PROFIT FOR THE PERIOD FROM CONTINUING OPERATIONS	153	132	16%
LOSS FROM DISCONTINUING OPERATION	4	8	-57%
NET PROFIT FOR THE PERIOD	149	123	21%
EPS Rs.	1.2	1.0	
NET PROFIT BEFORE DISCONTINUING OPERATION			
	153	132	16%
Loss from discontinuing operation	4	8	-57%
NET PROFIT FOR THE PERIOD	149	123	21%
# Licensing Income	10	8	
* Gross Research & Development expenses	142	139	